IN2014DN10592A - - Google Patents

Info

Publication number
IN2014DN10592A
IN2014DN10592A IN10592DEN2014A IN2014DN10592A IN 2014DN10592 A IN2014DN10592 A IN 2014DN10592A IN 10592DEN2014 A IN10592DEN2014 A IN 10592DEN2014A IN 2014DN10592 A IN2014DN10592 A IN 2014DN10592A
Authority
IN
India
Prior art keywords
hydroxysafflor yellow
salts
platelet aggregation
monomer compounds
hydroxysafflor
Prior art date
Application number
Inventor
Fengqi Ye
Ben Cai
Min Lu
Yongling Chen
Original Assignee
Zhejiang Yongning Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201310048480.4A external-priority patent/CN103980240B/en
Priority claimed from CN201310231483.1A external-priority patent/CN104230864A/en
Application filed by Zhejiang Yongning Pharmaceutical Co Ltd filed Critical Zhejiang Yongning Pharmaceutical Co Ltd
Publication of IN2014DN10592A publication Critical patent/IN2014DN10592A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Provided are new hydroxysafflor yellow A pharmaceutical salts as presented in formula (I), in particular new monomer compounds of potassium, ammonium, calcium, and magnesium salts of hydroxysafflor yellow A , preparation method therefor, and medical uses thereof. Compared to hydroxysafflor yellow A , the hydroxysafflor yellow A pharmaceutical salts of the present invention have a purity of at least 98% and are monomer compounds that are safer, more effective, stable, and controllable. The salts have the effects against PAF- or ADP -induced platelet aggregation, and can b e used in treating blood circulatory disorders such as platelet aggregation, coronary artery diseases, angina, and acute cerebral ischemia to the effect comparable t o hydroxysafflor yellow A . M and n are defined as in the description.
IN10592DEN2014 2013-02-07 2014-02-26 IN2014DN10592A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201310048480.4A CN103980240B (en) 2013-02-07 2013-02-07 New Hydroxy Carthamus yellow pharmaceutical salts
CN201310231483.1A CN104230864A (en) 2013-06-08 2013-06-08 Novel hydroxysafflor yellow A divalent medicinal salts, and preparing method and uses thereof
PCT/CN2014/000180 WO2014121666A1 (en) 2013-02-07 2014-02-26 New hydroxysafflor yellow pharmaceutical salts

Publications (1)

Publication Number Publication Date
IN2014DN10592A true IN2014DN10592A (en) 2015-09-11

Family

ID=51299238

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10592DEN2014 IN2014DN10592A (en) 2013-02-07 2014-02-26

Country Status (3)

Country Link
US (1) US9624254B2 (en)
IN (1) IN2014DN10592A (en)
WO (1) WO2014121666A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109044971A (en) * 2018-07-25 2018-12-21 浙江中医药大学 A kind of hydroxyl carthamin yellow A-containing self-micro emulsion formulation and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100427107C (en) 2006-06-24 2008-10-22 太原华卫药业有限公司 Preparation of safflower injection
CN101195647B (en) 2006-12-06 2010-08-18 山西华辉凯德制药有限公司 Hydroxyl carthamus tinctorius yellow colour A, preparation method and application thereof
CN101168539B (en) 2007-12-04 2011-01-19 哈药集团中药二厂 Method for extracting salvianolic acid B
CN102068478B (en) * 2010-12-13 2012-04-18 周国龙 Safflower injection and preparation method thereof
CN102675379B (en) 2011-03-15 2015-08-19 河北以岭医药研究院有限公司 A kind of method of Hydrolysis kinetics hydroxyl radical carthamin yellow carthamus A from safflower
CN102702150B (en) * 2012-06-19 2014-09-17 浙江永宁药业股份有限公司 Preparation method and application of hydroxysafflor yellow A
CN103980239B (en) * 2013-02-07 2016-04-13 浙江永宁药业股份有限公司 Hydroxyl radical carthamin yellow carthamus A sodium and production method thereof and purposes

Also Published As

Publication number Publication date
US20150197537A1 (en) 2015-07-16
US9624254B2 (en) 2017-04-18
WO2014121666A8 (en) 2015-02-19
WO2014121666A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
PH12015500106B1 (en) Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
CL2019001066A1 (en) Salt of (s) -csa of s-ketamine, salt of (r) -csa of s-ketamine and processes for the preparation of s-ketamine (divisional application 201702854)
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
CY1117183T1 (en) BRANCHED 3-PHENYLOPROPIONIC ACID PRODUCTS AND THEIR USE
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
MX2013011691A (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses.
IN2014DN07091A (en)
EA201592255A1 (en) DERIVATIVES OF PYRAZOLOPIRROLIDIN-4-IT AS A BET INHIBITOR AND THEIR APPLICATION IN THE TREATMENT OF THE DISEASE
MX2016005668A (en) Crystalline forms of therapeutic compounds and uses thereof.
WO2017022962A8 (en) Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient
TN2016000107A1 (en) Substituted phenylalanine derivatives
WO2016112875A3 (en) Diphenyl derivative and uses thereof
EA201692270A1 (en) DERIVATIVES OF NAFTYRIDINDIONE
PH12015502203A1 (en) Phenyl derivative
IN2014DN10592A (en)
WO2017106367A8 (en) Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity
MD4763C1 (en) Pharmaceutical composition
MX2015010961A (en) Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals.
BR112014032264A8 (en) Composition for the treatment or prevention of diseases related to vascular permeability, containing imatinib or a pharmaceutically acceptable salt thereof as an active ingredient
MX2017012110A (en) Ahu377 crystal form, preparation method and use thereof.
ECSP15025570A (en) PIDOTIMOD FORMULATIONS
TH180428A (en) Senic Rivalok components and methods for their production and use.
TH167738B (en) 1H-1, 8-Naphthyridin-2-transfer as anti-proliferation compound.
UA113887C2 (en) 5-Aminotetrahydroquinoline-2-carboxylic acids and their applications